Meta-analysis on clinical study of western routine treatments combined with Tongxinluo capsule in treatment of angina pectoris
-
摘要: 目的 系统评价西药常规合用通心络胶囊治疗冠心病心绞痛的疗效。 方法 运用计算机检索2000年至2011年中国期刊网全文数据库(CNKI)、万方数据库、维普数据库和PubMed,并结合手工文献检索相关杂志、会议论文和学位论文,收集国内外公开发表的西药常规治疗+通心络胶囊治疗冠心病心绞痛的随机对照试验(RCT)。由2名研究者独立选择试验、评价质量、提取数据,并交叉核对。使用RevMan 4.2.2软件进行分析。 结果 纳入西药常规+通心络胶囊(治疗组)与西药常规(对照组)对照评价治疗冠心病心绞痛有效率的RCT 11项,其中9项评价了心电图异常的改善率,11项评价了心绞痛症状的改善率。心电图疗效评价,治疗组相对于对照组相对危险度(RR)值为1.40(95% CI:1.28~1.54),P<0.01;心绞痛症状疗效评价,治疗组相对于对照组RR值为1.25(95% CI:1.18~1.32),P<0.01。治疗组仅个别病例有轻微胃肠不适。 结论 在西医常规治疗的基础上合用通心络胶囊,能有效提高临床疗效,用药安全。Abstract: Objective To assess the effectiveness of western routine treatments combined with Tongxinluo capsule for angina pectoris. Methods The randomized controlled trials(RCTs) of western routine treatments combined with tongxinluo capsule for angina pectoris were collected through searching on computer from the following databases,CNKI(2000-2011),WanFang Data(2000-2011),WeiPu Data(2000-2011),PubMed(2000-2011) and manual search relevant journals,conference papers. Results A total of 11 studies were included and improvement rate of abnormal ECG were estimated in 9 studies and improvement rate of symptoms of angina were estimated in 11 studies.ECG clinical evaluation of the treatment group relative to the control group,relative risk (RR) value was 1.40 (95% CI:1.28-1.54),P<0.01,symptoms of angina clinical evaluation,treatment group relative to the control group RR value of 1.25 (95% CI:1.18-1.32),P<0.01.Only slight gastrointestinal discomfort were found in treatment group. Conclusion Tongxinluo capsule in combination on the basis of conventional western treatment could effectively improve the clinical efficacy and drug safety.
-
Key words:
- combination of Chinese and western medicine /
- angina pectoris /
- efficacy /
- Meta-analysis
-
[1] Pace B,Lynm C.Benefits of physical activity for the heart[J].JAMA,2001,285(11):1536. [2] WHO.The global burden of disease [R].Geneva,2008. [3] 张文范.我国人口老龄化与战略性选择[J].城市规划,2002,26(2):68-72. [4] 陈红卫.通心络胶囊治疗冠心病心绞痛疗效观察[J].医学理论与实践,2002,15(10):1122-1123. [5] 冯 平,曾 海,李 萍.通心络胶囊治疗冠心病心绞痛疗效观察[J].中国中医急症,2003,12(6):534. [6] 郭晓梅.通心络胶囊治疗冠心病60例临床研究[J].疑难病杂志,2008,7(3):161-162. [7] 蒋义生.通心络胶囊治疗冠心病稳定型心绞痛的疗效观察[J].临床合理用药杂志,2010,3(20):66-67. [8] 金筠菁,何 彬.通心络胶囊治疗老年冠心病心绞痛临床疗效观察[J].中国民康医学,2003,15(9):526-528. [9] 李启云.通心络胶囊治疗冠心病、心绞痛合并高脂血症60例[J].菏泽医学专科学校学报,2004,16(2):19-21. [10] 李亚萍.通心络胶囊治疗冠心病心绞痛的疗效观察[J].中国校医,2003,17(6):486-488. [11] 骆小敏.通心络胶囊治疗冠心病心绞痛34例临床观察[J].中国医药导报,2010,7(32):56-57. [12] 齐 炜,齐 宏.通心络胶囊治疗冠心病心绞痛64例临床观察[J].中国民族民间医药,2010,19(24):127-128. [13] 王富收.不稳定型心绞痛临床治疗分析[J].中国实用医药,2011,6(21):94-95. [14] 张连祥,李春昕.通心络胶囊治疗冠心病心绞痛90例临床观察[J].医学研究与教育,2009,26(2):62-63. [15] Moher D,Pham B,Jones A,et al.Does quality of reports of randomised trials affect estimates of intervention efficacy reported in Meta-analyses[J].Lancet,1998.352(9128):609-613. [16] Kjaergard LL,Villumsen J,Gluud C.Reported methodologic quality and discrepancies between large and small randomized trials in Meta-analyses[J].Ann Intern Med,2001,135(11):982-989. [17] 谢景涛.中医药走向世界的产品策略[J].经济研究导刊,2011,(14):173-174. [18] 丁 炜,魏睦新.中医药走向世界,疗效才是硬道理[J].中国中医药咨讯,2010,2(36):74. [19] Juni P,Witschi A,Bloch R,et al.The hazards of scoring the quality of clinical trials for Meta-analysis[J].JAMA,1999,282(11):1054-1060. -
![WeChat](/fileYXSJZZ/journal/article/yxsjzz/2015/1/PIC/wechat_cn_20150124.jpg)
计量
- 文章访问数: 3750
- HTML全文浏览量: 188
- PDF下载量: 66
- 被引次数: 0